FIELD: medicine, pharmaceutics.
SUBSTANCE: there are described compounds of formula I: 
, their pharmaceutically acceptable salts where R1-R7, Y and n are specified in the patent claim. The compounds exhibit inhibitory action in the relation to aurora A tyrosine kinase. There is also described a drug of the compound of formula (I). The drug can be used for control or prevention of diseases, such as cancer.
EFFECT: preparation of new phthalazinone derivatives which can be used for control or prevention of diseases, such as cancer.
17 cl, 2 tbl, 41 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW COMPOUNDS | 2007 |
|
RU2456273C2 |
| CONDENSED TRIAZOLAMINES AS P2X7 MODULATORS | 2010 |
|
RU2533122C2 |
| 1,3-DISUBSTITUTED 4-METHYL-1H-PYRROL-2-CARBOXAMIDES AND USE THEREOF FOR PREPARING DRUGS | 2007 |
|
RU2463294C2 |
| PYRAZOLE DERIVATIVES APPLIED AS PROTEIN KINASE INHIBITORS | 2001 |
|
RU2340611C2 |
| BRUTON'S TYROSINE KINASE INHIBITORS | 2010 |
|
RU2542585C2 |
| NOVEL PYRAZOLE PYRIMIDINE DERIVATIVES | 2017 |
|
RU2769448C2 |
| NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES AND USE THEREOF IN PHARMACEUTICAL PREPARATIONS | 2013 |
|
RU2701156C2 |
| PYRAZOLPYRIMIDINE COMPOUNDS JAK INHIBITORS AND METHODS | 2009 |
|
RU2539568C2 |
| SERINE/THREONINE KINASE INHIBITORS | 2013 |
|
RU2650501C2 |
| HYDROXYLATED AND METHOXYLATED CYCLOPENTA[B]PYRIMIDINES AS PROTEIN KINASE INHIBITORS | 2007 |
|
RU2478632C2 |
